Target intelligence / Profile preview

Vinculin (VCL)

Target
VCL
Molecular classification
Cytoskeletal protein, Actin-binding protein, Focal adhesion protein, Adherens junction protein, Other (vinculin superfamily, sometimes linked to integrin-associated proteins)
01

Overview

Vinculin is a 117-kDa cytoskeletal actin-binding protein, highly conserved and ubiquitously expressed, comprising a head domain (binding talin, α-actinin, catenins), a proline-rich linker, and a tail domain (binding actin, paxillin, PIP2). Vinculin exists in closed (inactive) and open (active) conformations, mediating its ability to connect adhesion receptors on the membrane—primarily integrins—to the dynamic actin cytoskeleton. This connection stabilizes focal adhesions and adherens junctions, influences cell shape, regulates migration, and transmits mechanical signals. Metavinculin is a cardiac isoform with additional protein sequence and disease relevance. Disruption of vinculin impacts cell adhesion, migration, and can contribute to disease such as cancer and cardiomyopathy.

Other names
MetavinculinMVVINCCMD1WCMH15HEL114MVCLepididymis luminal protein 114epididymis secretory sperm binding proteinmeta-vinculin
02

Mechanism of action

Not applicable for drugs (no direct therapeutic targeting). Vinculin functions through conformational change (inactive/active states), regulated by ligand binding (e.g., talin, α-actinin, actin), and phosphorylation

03

Biological functions

Cell-matrix adhesionCell-cell adhesionMechanotransductionForce transmissionRegulation of cell shape, spreading, and motilitySuppression of migrationModulation of apoptosis and survival signalsOrganization of actin cytoskeleton
04

Disease associations

Cardiomyopathy (mutations have been linked to familial dilated and hypertrophic cardiomyopathy, especially via the metavinculin isoform)Cancer progression and metastasis (changes in vinculin expression affect cell migration, invasion, and metastasis)Developmental defects (knockout causes cardiac/neural tube defects, embryonic lethality)
05

Safety considerations

Not directly applicable, as vinculin is not a drug target.Genetic mutations or loss of function can lead to developmental defects or cardiomyopathyOverexpression or dysregulation might alter cell migration/cancer progression
06

Biomarkers

Used as a marker for focal adhesion and adherens junctionssometimes in histopathology/cancer studies to assess cell adhesion dynamics

Beyond the preview

Go deeper on Vinculin (VCL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vinculin (VCL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call